Patients suffering from a recurrent infection with the C difficile bacteria ... wave of new microbiome treatments. The Minnesota-based company is focused on developing drugs which use ‘good ...

Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...

Crucially, the drug doesn’t involve the use of antibiotics, which are the standard treatment for C. diff but are known to disrupt the healthy balance of the trillions of organisms in the gut ...

Vancomycin 265/309 (85.8%) 76/265 (25.3%) 198/309 (64.1%) † Clinical cure is resolution of diarrhea following the recommended dose of drug (fidaxomicin ... spectrum of treatment after results ...

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...

Unfortunately, only three antibiotics are available to treat C. difficile infections. The drug of choice for most patients is vancomycin, but in about one-third of patients, their infection ...

Acurx Pharmaceuticals (NASDAQ:ACXP) stock plunged 26% in midday trading amid the release of data from a Phase 2b clinical trial for its C. diff treatment ibezapolstat. The biotech company said the ...

Scientists have discovered how the hospital superbug C.diff rapidly evolves resistance to the frontline drug used for treatment in the UK. Clostridioides difficile (C. diff), a type of bacteria which ...

Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA ...

Risk of C. difficile-associated diarrhea; discontinue and treat if colitis is suspected ... Nursing mothers: consider alternative drug or monitor breast-fed infant for GI effects.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...